BALA CYNWYD, PA / ACCESSWIRE / August 17, 2019 / Brodsky & Smith, LLC reminds investors that it is investigating class action lawsuits against the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.
SUNLANDS TECHNOLOGY GROUP (NYSE:STG)
Shares purchased pursuant to the Company’s March 2018 initial public offering (IPO)
Deadline: August 26, 2019
According to the complaint, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sunlands’ student enrollment was declining; (2) Sunlands’ gross billings were declining; (3) Sunlands' marketing tactics were not as robust as described in the Registration Statement; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Additional information can be found at: http://www.brodskysmith.com/cases/sunlands-technology-group-nyse-stg/, or call: 877-534-2590. No cost or obligation.
CANNTRUST HOLDINGS INC. (NYSE:CTST)
Shares purchased between November 14, 2018 and July 5, 2019
Deadline: September 9, 2019
According to the complaint, the defendants failed to disclose to investors that: (1) CannTrust was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) CannTrust’s Pelham greenhouse did not comply with certain regulations; (3) as a result, CannTrust was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, CannTrust’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, the defendants’ positive statements about CannTrust’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Additional information can be found at: http://www.brodskysmith.com/cases/canntrust-holding-inc-nyse-ctst/, or call: 877-534-2590. No cost or obligation to you.
KARYOPHARM THERAPEUTICS, INC. (Nasdaq:KPTI)
Shares purchased between March 2, 2017 and February 22, 2019
Deadline: September 23, 2019
According to the complaint, defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Additional information can be found at: http://www.brodskysmith.com/cases/karyopharm-therapeutics-inc-nasdaq-kpti/, or call: 877-534-2590. No cost or obligation.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE: Brodsky & Smith, LLC